Club de Articulos

More

Code of Conduct

The Why, When and How

Twitter4Nephrons

Images of #NephJC

Club de Articulos

More

Code of Conduct

The Why, When and How

Twitter4Nephrons

Images of #NephJC

swapnil hiremath

November 26, 2018

Sirolimus to prevent recurrent squamous cell skin cancer, The Visual Abstract

swapnil hiremath

November 26, 2018

Screenshot 2018-11-26 19.21.01.png

By NSMC graduate, Angel Ortiz

Tagged: visual abstract, angel ortiz, sirolimus, DermJC, Visual Abstract

Newer PostThe NSMC and NephJC Code of Conduct

Older PostSirolimus as a Savior for Skin Cancer?

Tweet Feed

RT @Nephro_Sparks: This is a testament to all those who are and have been involved in the #NephTwitter movement. Will help to solidify… https://t.co/NhpTm3de7y
Sep 18, 2019, 11:54 AM
https://t.co/Yav1Kjo6xR NephJC is a non-profit organization; Get your nominees for the 4th annual #NephJCKidneys https://t.co/lXZ8LN4DJH
Sep 17, 2019, 2:44 PM
NephJC is a non-profit organization https://t.co/ngt0SV7RSQ
Sep 17, 2019, 12:39 PM
RT @IDJClub: #IDTwitter spoke, we listened: 📢Announcing @IDJClub, our very own Twitter journal club! On 1st Mondays @ 9EST, we… https://t.co/vNmSQavJPR
Sep 15, 2019, 6:05 PM
RT @GermHunterMD: #IDTwitter, we have a Twitter journal club! Please follow @IDJClub & join in the discussions using #IDJClub! Many… https://t.co/nITlUscC67
Sep 15, 2019, 6:05 PM
RT @Nephro_Sparks: 7/ @NephJC team and participant Always showing up to chats and participating in discussion. Leading and producing content
Sep 14, 2019, 1:54 PM
Get ready for the 2019 NephJC Kidneys https://t.co/qsVYpRwRj6
Sep 11, 2019, 9:07 AM
Last week #NephJC focused on autosomal dominant tubulointerstitial kidney disease and a possible treatment target. - https://t.co/MFpbd7mYXc
Sep 10, 2019, 8:00 AM
RT @VMJ_SVM: Get ready for the next #VascMedJC by reviewing this recent article on #PAD and #KidneyDisease… https://t.co/fr3krajPOK
Sep 8, 2019, 6:02 PM
RT @Nephro_Sparks: Total numbers over all #MUC1 chats : 613 Tweets. 97 Participants. 3,871,676 Impressions. September 2nd 2019. More… https://t.co/xkxIIClNt5
Sep 8, 2019, 6:02 PM
RT @Nephro_Sparks: #NephJC over last few days talking #BiomedicalResearch #NephForward https://t.co/EWC3WhrwfA
Sep 8, 2019, 6:02 PM
RT @NephJC_Podcast: Filtrate @Nephro_Sparks is prepping for that #NephJC #FridayFeeling with ... 🐁🐁🐁🐁🐁🐁🐁🐁🐁🐁 🐁🐁🐁🐁🐁🐁🐁🐁🐁 🐁🐁🐁🐁🐁🐁🐁🐁 🐁🐁🐁🐁🐁🐁🐁… https://t.co/tolyBzHSVX
Sep 8, 2019, 6:02 PM
Final call...Thanks to the excellent group we had joining us tonight, clinical physicians and basic researchers ali… https://t.co/3cdDTQICzK
Sep 4, 2019, 5:00 PM
Join us for our next #NephJC September 24th and 25th! #NephJC
Sep 4, 2019, 4:48 PM
Thanks everyone for your participation in tonight’s discussion! #NephJC
Sep 4, 2019, 4:47 PM
T3d: Any final thoughts or comments? #NephJC
Sep 4, 2019, 4:44 PM
Does this represent a potential therapeutic target for a common form of familial kidney disease? #NephJC
Sep 4, 2019, 4:43 PM
T3b: What are some limitations, if any, to bringing BRD4780 or even TMED9 CRISPR forward for clinical translation? #NephJC
Sep 4, 2019, 4:42 PM
T3a: What were your favorite strengths of the paper? #NephJC
Sep 4, 2019, 4:41 PM
T3: Phew! Some fascinating concepts. Let's move on to the discussion. #NephJC
Sep 4, 2019, 4:40 PM

Captopril@NephJC.com